Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 07:30 ET
|
Mereo BioPharma Group plc
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET
|
Mereo BioPharma Group plc
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
March 05, 2024 07:30 ET
|
Mereo BioPharma Group plc
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
January 08, 2024 07:00 ET
|
Mereo BioPharma Group plc
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
October 23, 2023 16:01 ET
|
Mereo BioPharma Group plc
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an...
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 21, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
September 07, 2023 07:30 ET
|
Mereo BioPharma Group plc
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Present at the Jefferies Healthcare Conference
May 31, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
May 23, 2023 13:43 ET
|
Mereo BioPharma Group plc
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 08, 2023 12:46 ET
|
Mereo BioPharma Group plc
LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...